Explore

Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects

Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects

Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects
Trendline Trendline
Regenxbio Shares Plummet Despite Positive Data for DMD Gene Therapy Candidate

Regenxbio Shares Plummet Despite Positive Data for DMD Gene Therapy Candidate

Regenxbio Shares Plummet Despite Positive Data for DMD Gene Therapy Candidate
Trendline Trendline
Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations
Trendline Trendline
Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal
Trendline Trendline
Regeneron, Dominion Energy, and Macy's Lead Premarket Stock Movements Amid Key Developments

Regeneron, Dominion Energy, and Macy's Lead Premarket Stock Movements Amid Key Developments

Regeneron, Dominion Energy, and Macy's Lead Premarket Stock Movements Amid Key Developments
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Major Stock Movements: Regeneron, Dominion Energy, and Macy's See Significant Changes

Major Stock Movements: Regeneron, Dominion Energy, and Macy's See Significant Changes

Major Stock Movements: Regeneron, Dominion Energy, and Macy's See Significant Changes
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026